Biora Therapeutics, Inc.
BIOR · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $4 | $305 | $1,247 | $74,313 |
| % Growth | -98.7% | -75.5% | -98.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $93,433 |
| Gross Profit | $4 | $305 | $1,247 | -$19,120 |
| % Margin | 100% | 100% | 100% | -25.7% |
| R&D Expenses | $29,838 | $24,049 | $45,785 | $47,743 |
| G&A Expenses | $0 | $0 | $68,541 | $75,438 |
| SG&A Expenses | $37,309 | $38,037 | $73,299 | $128,325 |
| Sales & Mktg Exp. | $0 | $0 | $4,758 | $5,949 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $67,147 | $62,086 | $119,084 | $176,068 |
| Operating Income | -$67,143 | -$61,781 | -$117,837 | -$107,619 |
| % Margin | -1,678,575% | -20,256.1% | -9,449.6% | -144.8% |
| Other Income/Exp. Net | -$57,281 | $12,531 | -$60,803 | -$34,999 |
| Pre-Tax Income | -$124,424 | -$49,250 | -$178,640 | -$142,618 |
| Tax Expense | -$90 | -$420 | -$119 | -$37,532 |
| Net Income | -$124,115 | -$38,157 | -$178,521 | -$192,528 |
| % Margin | -3,102,875% | -12,510.5% | -14,316% | -259.1% |
| EPS | -78.7 | -6.4 | -46.42 | -86.3 |
| % Growth | -1,129.7% | 86.2% | 46.2% | – |
| EPS Diluted | -78.7 | -6.4 | -46.42 | -86.3 |
| Weighted Avg Shares Out | 1,577 | 7,635 | 3,846 | 2,231 |
| Weighted Avg Shares Out Dil | 1,577 | 7,635 | 3,846 | 2,231 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $9,815 | $10,990 | $12,636 | $9,915 |
| Depreciation & Amortization | $555 | $907 | $1,437 | $1,438 |
| EBITDA | -$114,054 | -$37,353 | -$164,567 | -$106,181 |
| % Margin | -2,851,350% | -12,246.9% | -13,197% | -142.9% |